Novo Nordisk's Wegovy pill has rapidly gained traction in the U.S. GLP-1 weight loss drug market, outpacing Eli Lilly's Foundayo pill, which launched three months later. According to LifeMD CEO Justin Schreiber, the introduction of the Wegovy pill in January led to a doubling of new patient sign-ups, with daily numbers rising from 300-400 to 600-1,000, highlighting the significant demand for oral GLP-1 medications [1]. Tens of thousands of people have started taking the Wegovy pill in the four months since its U.S. launch, with the majority being new to the GLP-1 category [1].
The strong debut of Wegovy has prompted investors to reconsider their expectations for the oral GLP-1 market, which many previously believed would be dominated by Eli Lilly due to its manufacturing advantages and prior success with injectable GLP-1 drugs. However, early signs indicate that Foundayo's rollout has been more modest compared to Wegovy's robust start [1]. Analyst Evan David Seigerman from BMO Capital Markets noted that initial investor sentiment favored Lilly's Foundayo, especially given concerns about Novo's peptide production capacity, but Novo's aggressive marketing and the efficacy of oral semaglutide (the active ingredient in Wegovy) have shifted perceptions [1].
Clinical trial data cited in the article shows that Lilly's pill helped people lose about 12% of their body weight on average, while Novo's oral semaglutide delivered nearly 17% weight loss in a separate trial [1]. Novo Nordisk capitalized on this efficacy advantage with a high-profile promotional campaign, including subway and TV ads and a Super Bowl commercial featuring DJ Khaled. The company also emphasized the pill's lower entry price of $149 per month [1].
Investors are awaiting Novo Nordisk's first-quarter results, which are expected to provide further insight into the momentum of the Wegovy pill [1]. The early success of Wegovy has disrupted expectations and forced a reassessment of which company might ultimately lead the oral GLP-1 market [1].
CONCLUSION
Novo Nordisk's Wegovy pill has quickly established a strong foothold in the U.S. oral GLP-1 weight loss market, surpassing Eli Lilly's Foundayo in early adoption and patient demand. The market is closely watching Novo's upcoming earnings for further confirmation of this momentum, as investor sentiment shifts in favor of Novo's competitive position.